170 related articles for article (PubMed ID: 33002130)
21. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
22. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
23. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Samra B; Alotaibi AS; Short NJ; Khoury JD; Ravandi F; Garris R; Jain N; Konopleva M; Kantarjian H; Jabbour E
Am J Hematol; 2020 Sep; 95(9):E245-E247. PubMed ID: 32501545
[No Abstract] [Full Text] [Related]
24. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
Summers RJ; Teachey DT
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort.
Goto H; Ogawa C; Iida H; Horibe K; Oh I; Takada S; Maeda Y; Minami H; Nakashima Y; Morris JD; Kormany W; Chen Y; Miyamoto T
Acta Haematol; 2022; 145(6):592-602. PubMed ID: 35790143
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.
Lv M; Liu Y; Liu W; Xing Y; Zhang S
Front Immunol; 2022; 13():921894. PubMed ID: 35769486
[TBL] [Abstract][Full Text] [Related]
27. CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia
.
Callahan C; Baniewicz D; Ely B
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):22-28. PubMed ID: 28315553
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
Temple WC; Mueller S; Hermiston ML; Burkhardt B
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101449. PubMed ID: 36907639
[TBL] [Abstract][Full Text] [Related]
29. Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.
Huang J; Rong L; Wang E; Fang Y
Immunotherapy; 2021 Jan; 13(1):5-10. PubMed ID: 33045890
[No Abstract] [Full Text] [Related]
30. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
Malone A; Smith OP
Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
[No Abstract] [Full Text] [Related]
31. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
[TBL] [Abstract][Full Text] [Related]
33. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
34. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
35. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
Bandapalli OR; Schuessele S; Kunz JB; Rausch T; Stütz AM; Tal N; Geron I; Gershman N; Izraeli S; Eilers J; Vaezipour N; Kirschner-Schwabe R; Hof J; von Stackelberg A; Schrappe M; Stanulla M; Zimmermann M; Koehler R; Avigad S; Handgretinger R; Frismantas V; Bourquin JP; Bornhauser B; Korbel JO; Muckenthaler MU; Kulozik AE
Haematologica; 2014 Oct; 99(10):e188-92. PubMed ID: 24972766
[No Abstract] [Full Text] [Related]
36. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
[TBL] [Abstract][Full Text] [Related]
38. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
39. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
40. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
Hu GH; Zhao XY; Zuo YX; Chang YJ; Suo P; Wu J; Jia YP; Lu AD; Li YC; Wang Y; Jiao SC; Zhang LJ; Kong J; Yan CH; Xu LP; Zhang XH; Liu KY; Cheng YF; Wang Y; Zhang LP; Huang XJ
Leukemia; 2021 Nov; 35(11):3092-3100. PubMed ID: 33824464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
